A Brief Overview of the Paradoxical Role of Glucocorticoids in Breast Cancer. (December 2020)

• Record Type: Journal Article
• Authors: Zhidkova, Ekaterina M; Lylova, Evgeniya S; Savinkova, Alena V; Mertsalov, Sergey A; Kirsanov, Kirill I; Belitsky, Gennady A; Yakubovskaya, Marianna G; Lesovaya, Ekaterina A
• Is Part Of: Breast cancer. Volume 14(2020)
• Publication Date: 2020-12
• Subjects: Breast cancer -- glucocorticoid -- glucocorticoid receptor -- selective glucocorticoid receptor agonists (SEGRA) -- REDD1 -- breast cancer metastasis; Breast -- Cancer -- Periodicals; 616.99449
• DOI: 10.1177/1178223420974667
• Languages: English
• ISSNs: 1178-2234

Abstract

Glucocorticoids (GCs) are stress hormones that play multiple roles in the regulation of cancer cell differentiation, apoptosis, and proliferation. Some types of cancers, such as hematological malignancies, can be effectively treated by GCs, whereas the responses of epithelial cancers to GC treatment vary, even within cancer subtypes. In particular, GCs are frequently used as supporting treatment of breast cancer (BC) to protect against chemotherapy side effects. In the therapy of nonaggressive luminal subtypes of BC, GCs can have auxiliary antitumor effects due to their cytotoxic actions on cancer cells. However, GCs can promote BC progression, colonization of distant metastatic sites, and metastasis. The effects of GCs on cell proliferation vary with BC subtype and its molecular profile and are realized via the activation of glucocorticoid receptor (GR), a well-known transcriptional factor involved in the regulation of the expression of multiple genes, cell-cell adhesion, and cell migration and polarity. This review focuses on the roles of GC signaling in the adhesion, migration, and metastasis of BC cells. We discuss the molecular mechanisms of GC actions that lead to BC metastasis and propose alternative pharmacological uses of GCs for BC treatment.